2740 T3D2698 Folic acid Folic acid is a member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (poaceae). Folic acid, being biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase. These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylated tRNA, and generate and use formate. Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. 59-30-3 6037 C19H19N7O6 441.139680 White powder. 250 dec°C 1.6 mg/L (at 25°C) Intravenous, Oral Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase. These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase. Hepatic Route of Elimination: Folic Acid is metabolized in the liver to 7, 8-dihydrofolic acid and eventually to 5,6,7,8-tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide (DPNH) and folate reductases. A majority of the metabolic products appeared in the urine after 6 hours; excretion was generally complete within 24 hours. Folic Acid is also excreted in the milk of lactating mothers. LD50: 85 mg/kg (Intraperitoneal, Mouse) (A308) LD50: 120 mg/kg (Intravenous, Guinea pig) (A308) LD50: 239 mg/kg (Intravenous Mouse) (A308) LD50: 500 mg/kg (Intravenous, Rat) (A308) LD50: 410 mg/kg (Intravenous, Rabbit) (A308) No indication of carcinogenicity to humans (not listed by IARC). For treatment of folic acid deficiency, megaloblastic anemia and in anemias of nutritional supplements, pregnancy, infancy, or childhood. 2009-07-21T20:26:10Z 2026-03-27T01:22:50Z Folic_Acid C00504 136610 136630 229050 229100 236200 236250 309548 601634 601775 603174 608866 27470 FOLATE Folic Acid DB00158 FOL 2649 true NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1 C19H19N7O6 InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1 OVBPIULPVIDEAO-LBPRGKRZSA-N 441.3975 441.139681375 Endogenous Solid -2.5 HMDB00121 CHEMBL1622 5815 <p>Carroll G. Temple, Jr., Robert D. Elliott, Jerry D. Rose, John A. Montgomery, &#8220;Preparation of tetrahydrofolic acid from folic acid.&#8221; U.S. Patent US4206307, issued April, 1956.</p> CHEM002130 DTXSID0022519 NS00007261 (2S)-2-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)formamido]pentanedioic acid